Autres langues

26/06 Resverlogix Announces Voting Results from the 2026 Meeting of Shareholders
19/05 Resverlogix Closes US$2 Million Shares-for-Interest Private Placement
16/05 Resverlogix : Financial Statement Q1 2026
16/05 Resverlogix : MD&A Q1 2026
15/05 Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026
11/05 Resverlogix Corp. Announces One-Year Extension of USD 6.0 Million Secured Debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd
11/05 Resverlogix Announces One-Year Extension of Debenture
16/04 Resverlogix Corp. Announces Filing of Annual Filings and Revocation of MCTO
11/04 Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2025
11/04 Resverlogix : Annual Information Form 2025
11/04 Resverlogix : Financial Statement Q4 2025
10/04 Resverlogix Corp. Auditor Raises 'Going Concern' Doubt
02/04 Resverlogix Corp. Announces Issuance of MCTO by ASC
01/04 Resverlogix Corp. Provides Bi-Weekly MCTO Status Update
18/03 Resverlogix Announces Delay in Filing of Annual Financial Statements, AIF, and MD&A
19/02 Resverlogix Closes $2.8 Million Shares-for-Interest Private Placement
19/11 Resverlogix Appoints Bradley Glass to Board of Directors
18/11 Resverlogix Appoints Bradley Glass to Board of Directors
14/11 Resverlogix : MD&A Q3 2025
14/11 Resverlogix : Financial Statement September 30, 2025
14/11 Resverlogix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
14/08/25 Resverlogix : MD&A Q2 2025
14/08/25 Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
30/06/25 Resverlogix Announces Voting Results from the 2025 Meeting of Shareholders
23/05/25 Resverlogix : Annual Meeting of Shareholders - Notice and Access
Aucun résultat pour cette recherche